Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Fortune 500

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

World's Most Admired Companies

Industries included in the sector are home equipment and furnishings and household and personal products.

Fortune Sector Leaders: Household Products

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-188-Colgate-Palmolive

Founded as a small soap and candle business in 1806, the consumer products company now boasts a portfolio of well-known household and personal care brands.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-203-Colgate-Palmolive

Colgate-Palmolive's diverse portfolio of home, personal, and oral care brands—which includes names like Ajax, Irish Spring, and Speedstick—are sold in more than 200 countries and territories.

As we face unprecedented collective challenges, cooperation has become a business superpower.

27.CTW20.Colgate-Palmolive2

Toothpaste tubes have long frustrated green-minded consumers. The hybrid composition that makes such tubes squeezable—a mixture of laminated plastic and aluminum—also makes it impracticable to recycle most of the 20 billion tubes that consumers discard each year.<br />
<br />
Colgate-Palmolive, which claims 41% of the global toothpaste market, poured five years of research into this puzzle, and in 2019, the effort paid off. Colgate’s new recyclable tube is made from high-density polyethylene (HDPE), the recyclable plastic found in shampoo containers and milk jugs. (A key phase of the research: grinding down the tube prototypes and recycling them as new bottles.) This year, Colgate introduced the tubes in multiple brands and it will soon use them for Optic White, which alone accounts for 8.5% of U.S. toothpaste sales. The company aims to make 100% of its packaging recyclable by 2025. In the meantime, it’s sharing the HDPE design on an open-source basis, so others can adopt it too.

Change the World

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fortune Global 500

Change The World

Impact Segment

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Colgate-Palmolive, founded in 1806, manufactures and sells hygiene products in the U.S. and internationally. Its wide variety of offerings range from toothpaste and toothbrushes to hand soaps, shampoos, and household cleaners. Popular brands include Palmolive, Tom’s of Maine, Irish Spring, Softsoap, Speed Stick, and Fabuloso. It’s also the parent company of Hill’s Pet Nutrition, which sells its products through pet supply retailers and veterinary clinics.

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Colgate-Palmolive (CL): Company Profile, Stock Price, News, Rankings

legacy

Colgate-Palmolive

colgate-palmolive

Good morning. Welcome to today's Colgate-Palmolive third quarter 2025 earnings conference call. This call is being recorded and is being simulcast live at www.colgatepalmolive.com. Now, for opening remarks, I'd like to turn this call over to Chief Investor Relations Officer and Executive Vice President, M&A, John Faucher.

Thanks, Drew. Good morning and welcome to our third quarter 2025 earnings conference call. Today's conference call will include forward-looking statements. Actual results could differ materially from these statements. Please refer to our third quarter 2025 earnings press release and related prepared materials, and our most recent filings with the SEC, including our 2024 annual report on Form 10-K and subsequent SEC filings, all available on Colgate-Palmolive's website for discussion of the factors that could cause actual results to differ materially from these statements. Our remarks will also include a discussion of non-GAAP financial measures, which excludes certain items from reported results, including those identified in tables four, six, seven, eight, and nine of the earnings press release. A full reconciliation to the corresponding GAAP financial measures is included in the third quarter 2025 earnings press release and is available on Colgate-Palmolive's website.

Joining me on the call this morning are Noel Wallace, Chairman, President, and Chief Executive Officer, and Stan Sutula, Chief Financial Officer. Noel will provide you with some thoughts on our Q3 results and our future plans, and then we will open up for Q&A. Noel?

Thanks, John, and good morning, everyone. Thanks for joining us today as we discuss our Q3 results and, more importantly, the steps we are taking to accelerate our performance in this volatile operating environment. Importantly, focused on the priorities and actions set out in our 2030 strategy. As you will hear today, consumer uncertainty, tariffs, geopolitics, high-cost inflation, and other factors are all pressuring sales and profit growth across the consumer sector. Despite these headwinds, we are operating with determination and focus. We have healthy brands and growing categories with strong market shares and a diverse global footprint, with nearly 50% exposure to faster-growth emerging markets and a best-in-class global supply chain to service that demand.

We remain committed to our goals of delivering organic sales growth, net sales growth, and dollar-based EPS growth, and to our capital allocation priorities to drive total shareholder return towards the top end of our peer group. We have done that over the past five years and have confidence in our ability to continue to do that. What drives this confidence is our ability to execute on our 2030 strategy to accelerate change as we adapt to this complex and changing environment. Coming off our 2025 strategic plan, we have improved our innovation, built and scaled our capabilities, improved our organic sales and market share performance, and delivered consistent annual dollar-based EPS growth. This is the perfect time for our strategic transition as we're coming off our 2025 plan, which built the organizational muscle necessary to execute our strategy and focus on global alignment.

This is not wholesale change, but rather we are working to accelerate the rate of change as we embark on our 2030 strategy. We have made and are continuing to make the changes that are required to drive outperformance, and over the strategic time horizon of our 2030 strategy, we will emerge a stronger and more effective company. As I outlined in September, we are taking concrete, intentional steps to accelerate our growth going forward, steps that will drive performance in any market environment, but particularly important now. These include a new innovation model with additional resources focused on delivering more impactful, science-based innovation across all price tiers. This new model includes investment in people. Process improvement, and resources and tools, including AI, to make us faster and better able to prioritize the innovative products and packaging that matter most to our customers and consumers.

We are focused on omnichannel demand generation, including upskilling our commercial organization to be more consumer-centric by adopting how we deliver the right products with the right content, with the right message, to the right people at the moments that matter. This will help continue to build the strength of our brands and drive brand penetration. Having scaled new capabilities we prioritize as part of our 2025 strategy, including digital, data, analytics, and AI, we will drive more dynamic change by accelerating our investments and efforts in areas like RGM and agentic AI, working to drive efficiency, disrupt our own processes, and integrate new ways of working across the company. Using predictive analytics and automation more and more across our supply chain to deliver personalization at scale, drive optimal asset utilization, minimize downtime, improve our service levels, and enhance our quality systems.

Underpinning many of these initiatives is our Strategic Growth and Productivity Program. While this program will enable us to fund incremental investments and deliver savings to drive dollar-based earnings growth, it is even more vital as a strategic enabler to facilitate the changes in behaviors and processes needed to accelerate organizational change, making us more flexible and simplifying our processes to increase speed and efficiency. Because of these actions and the fundamentals of our business, we believe we are well-positioned to outperform in the context of the current global category slowdown for several reasons. The strength of our business in emerging markets gives us the ability to drive faster category growth as developed markets remain sluggish. Hill's underlying performance remains very good in a softer category, given our robust innovation and our ability to gain market share in low-development segments like cat, wet, and small-pause.

The health of our brands across categories following years of investment provides us with opportunities to drive pricing to offset raw material inflation. Across our business units, we continue to have well-funded advertising and innovation plans, and we're operating with an even greater focus on revenue growth management, particularly with prescriptive analytics and AI. We continue to generate strong cash flow to invest in the business and help drive TSR. The timing for us to be kicking off our 2030 strategy could not be better. We are seizing this moment as the 34,000 Colgate-Palmolive people around the world work to deliver on the change needed to re-accelerate growth and outperform. With that, I'll take your questions.

We will now begin the question-and-answer session. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please limit yourself to one question. If you have further questions, you may re-enter the question queue. Once again, if you would like to ask a question, please press star then one. The first question comes from Dara Mohsenian with Morgan Stanley. Please go ahead.

Clearly a difficult operating environment here in terms of category growth and household products, as you mentioned, Noel, with all the consumer pressure points. Can you just give us some perspective on if you expect the category softness to linger as we look out to 2026? You also highlighted a number of focus areas for your own business in 2026 within that landscape. Just how impactful and quickly do you think those levers might be in improving your own organic sales growth performance, again, as we look beyond this year? If I can just flip to part B, can you just review Hill's specifically? Volume mix dropped off in the quarter. I know there's some factors exaggerating that, but it did look like the underlying performance was perhaps weaker. Just an update on pet category trends and Hill's market share performance specifically would also be helpful. Thanks.

Great. Thanks, Dara. Clearly a lot of volatility in the market, particularly in the quarter. We're seeing month-to-month swings that are, quite frankly, pretty surprising through the quarter. August was very difficult, but September shipments did get better, just not enough to make up for the August softness we saw. If I look back at my upfront comments, which I think clearly lay out exactly how we're thinking about the business both short-term and long-term, as we switch to our 2030 strategy, we feel we're in a position of strength here. We're executing against the changes that we implemented through 2025 and the new changes that we believe contemplate the current environment, which we expect to continue in the short term, certainly to be sluggish.

The SGPP will provide the right organizational structure and the capabilities while funding, importantly, increased investment and helping us drive that dollar-based earnings per share growth we talked about. If I go around the world, perhaps in terms of the operating environment, on an underlying basis, we think North America was actually a little better for us this quarter, and particularly excluding skin health, but we're still not where we need to be there. I'm pleased to see how Shane and John Kooyman are truly tackling the opportunities that we see on the business. Categories were slightly weaker in Q3 in North America, but our performance improved sequentially, and we expect that to continue sequentially, particularly excluding skin health. Consumer still remains relatively weak across North America, as you point out. We're seeing higher levels of couponing. Hispanic traffic is still down.

As you've heard from others, category takeaway in the U.S., particularly in September, was a little softer than most of us anticipated and a little softer than preceding months. If I move on, again, we expect that to continue. This SGPP plan, Dara, what I'm really trying to get across here is we're anticipating a continued sluggishness, but we're making the changes necessary to stimulate growth not only for our business but for the categories. That's going to be consistent all over the world. As expected, let me get into Europe. We're seeing a little less pricing than before. Volume was in line, maybe slightly lower than we were expecting. Western Europe was strong, better than we expected. Some incremental weakness in Eastern Europe, particularly in Poland. Latin America is mixed, although Mexico and Brazil are better for us than for some others.

Organic was up mid-single digits in both Mexico and Brazil. Conversely, Colombia and Central America were a little softer as they're dealing with more economic weaknesses in those markets and more political volatility that's impacting consumption across those regions. If I move on now to perhaps China, China is a mixed bag for us. Colgate continues to do well as e-commerce and innovation are key drivers for us in that market and doing exceptionally well. We were up mid-single digits on the Colgate side. However, [Dali] continued to see some weakness, particularly in premium e-commerce. We are taking aggressive steps to address our innovation and our e-commerce business there, but it's taken a little longer than we anticipated to see the changes. As you saw in the announcement, India was a little softer, but we expect that to improve moving forward. The GST came through in the quarter.

Medium and long-term positive, we think, for the benefit. It created some additional headwinds as we went into the quarter, as we exited the quarter. Importantly, we are really focused on getting some big core innovations executed across that country and pushing our premium innovation, particularly in the urban class of trade where we've seen some sluggishness. Let me move on to Hill's quickly to balance out your question at the end. Hill's, from a category, remains a bit soft, but we particularly saw dog dry down, but cat way up. U.S. growth slowed a bit, but that included some headwinds from lower e-commerce inventory that got pulled out at the end of the quarter. A little softness in Canada due to the Canadian sentiment, but overall, we're pleased with Hill's.

If you take ex-private label up, some good growth there, and we're gaining share there across almost every strategic growth segment there is. That, again, is, I think, a testament to the strategy we put in place the last couple of years, the increased capacity we have in areas like wet. We obviously are expecting the category to remain a little bit sluggish in the short term, but the opportunities for growth remain real, particularly in those faster-growing segments like cat and wet, and we believe we've got the plans in place to do that. Despite. A positive growth in our categories, but slower than we anticipated in the quarter, raw material inflation, tariffs, obviously some trade destocking, we're still delivering dollar-based earnings per share and strong cash flow. Overall, that's exactly how we expect the business to continue to trend.

The next question comes from Peter Grom with UBS. Please go ahead.

I wanted to ask on Latin America. I just wanted to ask on Latin America. First, just the prepared remarks, there was a comment regarding a decline in oral care due to the replacement of trade inventories in connection with a formula change. Can you just give more color on what happened there, and is there a way to quantify the impact it had on the quarter? Second, and related, growth in the region has been more in this low single-digit range this year as pricing is moderated. Noel, your commentary to Dara's question was helpful. Just as we look ahead, would you expect more of the same, or do you see an opportunity for growth to improve from here? Thanks.

Sure. Thanks, Peter. Latin America organic was 17%, which includes 150 basis points negative from the volume impact from the Colgate Total replacement, which I'll talk to perhaps in a second here. As I mentioned just a second ago, we were pleased with Mexico and Brazil, both up around 4%. Overall, those markets continue to perform well. Pricing is improving, but a little bit at expense of volume. We saw volume a little bit sluggish in our categories, not to be expected given some of the prolonged pricing we've taken there. Let me explain a little bit more on Colgate Total. Globally, through the third quarter, Colgate Total continues to do well, driving organic sales growth and premiumization as we've been able to take pricing on this pretty significant innovation.

We've rolled it out around the world with new regiment claims and on toothpaste, mouthwash, and toothbrush, and seeing some good share growth in general around the world. We're pleased with that. If I go back to Latin America, we noticed an increase in consumer complaints, including some temporary mouth irritations in Latin America early in the year, with the majority coming from consumers who had used the clean mint variant. This was mostly people who brushed their teeth three, four, sometimes even five times a day. We determined this was primarily due to the new flavor. We adjusted the formula, and in collaboration with the Brazilian health authorities, we voluntarily replaced the impacted variants in Brazil with the reformulated product, and we've seen Colgate Total market shares begin to improve subsequent to that change. We are currently also replacing the impacted variants in other markets in Latin America.

This was the gross margin impact that we discussed in the prepared commentary, 40 to 50 basis points. While we did not see the same level of complaints in other markets, we are proactively adjusting the formula for the impacted variants around the world. There may be some further costs going forward, but at this point, we believe the majority of costs have already been incurred. Coming back to some of the categories in Latin America, still growing, but have slowed a little bit in the recent periods, driven by particularly volume while we're still getting pricing in the categories. This, as I mentioned just a moment ago, is more acute in Andina and Central America, where we're seeing a little bit more price competition in those markets. We're making the necessary changes to adjust to that, and we're working on sharpening our price points to improve our volume shares.

Overall, Latin America volume shares for our total oral care business were flat, slightly down in value, as I mentioned, due to perhaps the total replacement. We're starting to see those shares come back nicely.

The next question comes from Kaumil Gajrawala with Jefferies. Please go ahead.

Yeah, don't pressure anybody who is spending all that money on it.

Thank you, Kaumil. Please go ahead with your question.

I hate the year. I hate moments of the year.

Go to the next question. The next question comes from Filippo Falorni with Citi. Please go ahead.

Good morning. On the Asia-Pacific business, Noel, you mentioned the GST tax change, obviously impact on India. Any sense of quantifying that impact also? You mentioned an improvement going forward. Is that the main driver? Are you expecting also an improvement in the macro conditions there? Any comments on the local competition in the market will be helpful. Thank you.

Yeah. Filippo, let me address India first. Thank you. As you saw from the India company results, organic was down mid-singles. Underlying demand in India, mostly in the urban part, tends to be a bit sluggish. Rural seems to be holding up okay. We had very difficult comparisons, as you well know. Pleasingly, comps get easier, and we feel we've got really good plans moving forward. We expect better performance in the fourth quarter and returning, obviously, to growth in 2026. The GST tax in our categories, particularly oral care and toothpaste, went from 18%-5%. As you can imagine, this led to some price reductions and disruptions in trade inventories. I think our team did a really good job to manage that and get ahead of it and get it cleaned up as we move into the fourth quarter.

Longer term, we would expect the GST reduction to benefit consumption in the category, which has been challenged by the inflationary pressures there. Overall, we think this will be a net positive for us. Moving forward, we're obviously very focused on addressing some of the sluggishness we're seeing in the rural areas. We've got a strong premiumization strategy to continue to grow share in the modern trade and particularly in urban areas. We'll be reviewing that business in detail with the teams next week, but we're excited about some of the strategic areas that we're going after and the long-term growth potential of that market.

The next question comes from Robert Ottenstein with Evercore ISI. Please go ahead.

Great. Thank you very much. First, a quick follow-up. Just on Latin America, if you can give us just a sense of where the market shares ended up with the relaunch and your thought of the impact of the formula change on that, and what is the outlook for 2026? My main question is on the drugstore channel in the U.S. Very weak, not a great channel to shop in, products under lock and key. How are you dealing with the challenges of that channel? Perhaps related to that, Elmex has been a huge success in Europe. Drugstore channel in the U.S., not the greatest venue for that. How are you thinking about that dynamic, the weakness of the drugstore channel, as well as the potential of Elmex in the U.S.? Thank you.

Yeah. Thanks, Rob. Let me try to take those in turn. First, on Colgate Total, we got out of the gates really, really strong. With that relaunch, saw market shares grow incrementally for the business. As you can imagine, we stayed very close with our consumers, and as I outlined, made an adjustment to the flavor in order to address some consumer complaints and irritation associated with select variants. The good news is that new product is rolling in, particularly in Brazil and Mexico and across the region as we speak. The early indications are we're starting to see the shares come back quite nicely. We have a really strong marketing plan for the quarter to go, the quarter we're in right now. We're quite confident that we will see the business rebound nicely.

As I mentioned, it was about 150 basis points of negative organic in the quarter for Latin America, about 40 to 50 basis points of total gross margin hit. The good news is we're moving forward and confident in what we're seeing with Colgate Total. If I move to Asia, particularly where we're seeing some very strong results on Colgate Total, we're very encouraged by the progress we're seeing in that region. As I refer to your question around the drug class of trade, it is challenged. The good news is we have re-engaged them in conversations in the middle store about how to drive more traffic back into those stores. Obviously, CVS announced more improved results this week, as you may have seen. We're hopeful they're committed to getting the middle of the store addressed and certainly the therapeutic end of the business.

Our whitening business continues to do quite well there. They are challenged right now, and we're working very closely with them to improve the category dynamics through some of the revenue growth management initiatives and, more importantly, some of the high-end therapeutic premium innovation we're bringing to it. Elmex, wonderful business. I won't get into the discussion on Europe at this stage, but driving record shares for us in Europe. We have taken that bundle, to your point, Rob, into other key strong pharmacy markets around the world. It requires a strong professional underpinning in order to launch that. Clearly, we have opportunities to take that into other markets. As we decide to roll that into new markets around the world, we'll be sure to let you and other investors know because it's a wonderful bundle with great upside potential.

The next question comes from Robert Moskow with TD Cowen. Please go ahead.

Hi. Thanks for the question. I noticed in the script that in the U.S., you mentioned some increased competitive activity, getting more promotional. You described it as fairly rational. Can you be more specific as to the degree to which it's intensifying and what you expect going forward?

Yeah. Thanks, Rob. We've seen a slight uptick in promotional weights, more couponing, a little bit more volume on deal, but nothing that would suggest that we're back to pre-COVID levels and higher. It's still, in my view, quite constructive. You can imagine, as we've seen some volume slowdown in the categories in which we compete, I think all of the retailers and all the competitors are looking for solutions in order to drive more turn and more velocity in store. Ultimately, that turns to volume. What's interesting is when you look at the volume characteristics in the U.S., we still see the premium and the super premium growing very, very nicely. It's the value-oriented brands or SKUs or segment, as well as the mid-price segment, that seems to be suffering.

Importantly, as I outlined in our 2030 strategy, we are very deliberately looking at more core innovation across our franchises to stimulate more demand, particularly at the lower end, while we continue to focus on the significant growth opportunity we have in the premium segment around the world. The strategy is much more intentional in getting more innovation out to stimulate demand, not only here in North America, but around the world.

The next question comes from Lauren Lieberman with Barclays. Please go ahead.

Great. Thanks so much. Just wanted to ask about the pricing environment in Europe. I know we've had a few years, obviously, post-COVID, where there's pretty constructive pricing. This quarter is still positive, but just curious about kind of the longer-term outlook and ability to keep driving positive price in Europe. Thanks.

Yeah. Thanks, Lauren. Good morning. Clearly, as we've said, we're really pleased with continued pricing in Europe. I think we've learned a lot in the last couple of years on how to manage price effectively, notwithstanding the fact that it will continue to be a challenge in the longer term getting positive pricing every quarter. We have certainly built a much stronger muscle on the importance of ramping up our innovation. I come back to the SGPP and the focus we have on putting more resources into innovation. That's going to allow us to take price-based innovation, particularly at the premium side of the business, and that will be our focus. Overall, the retailers have to be pleased with the category growth they're seeing on dollars and our ability to get pricing in the category. It's going to be a balance.

We need to bring real science-based innovation to drive the premiumation and take more pricing. I would expect that pricing, our anticipation is that we can keep getting positive pricing as we move forward, but it will certainly be a little bit more challenged given the prolonged inflation that we've seen in the categories and our need to balance both pricing and volume growth moving forward.

The next question comes from Bonnie Herzog with Goldman Sachs. Please go ahead.

All right. Thank you. Good morning. I had a question on your implied Q4 organic sales growth. I guess for the full year, guidance assumes a step up in Q4 at the midpoint. I guess just hoping you could talk through the puts and takes for Q4 to get there. I guess I'm asking in the context of the still subdued end market backdrop and certainly the greater headwinds from private label pet food exit. Thank you.

Hi, Bonnie. It's Stan. Yes, let's talk a little bit about Q4. We said in our guidance that Q4 organic or that full year organic would be roughly in line with the year to date. If you look at the year to date, we're roughly at 1.2%. Getting to the full year would indicate that we'd improve over the performance in Q3. If you think about the drivers that would help there, we had an impact that Noel articulated earlier around Total to the total company. That's going to improve here as we go. You also heard in both our prepared commentary and some of the questions thus far that there was some destocking in certain markets and certain products. As that levels out, that also becomes a benefit here heading into Q4.

In addition, on private label, the impact that you saw in Q3 year-on-year will roughly be about the same impact that you'll see in Q4 as we have completely exited the private label business, but we still have that year-on-year impact. Right now, as we look at Q4 and coming off of Q3 in a momentum that we see, we feel pretty good about that in line for our guidance of roughly in line with the Q3 year to date, which is around 1.2%.

The next question comes from Kevin Grundy with BNP Paribas. Please go ahead.

Great. Thanks. Good morning, everyone. Noel, question for you. I wanted to kind of take a step back and get your thoughts on the top-line challenges, how much of this you believe is cyclical versus how much you believe maybe are Colgate-specific challenges. 1% organic sales growth in the quarter. I'm sure you're not pleased with it. It's levels that investors are less accustomed to seeing from Colgate. Number one, at a global level, where do you see industry growth at the moment, kind of rolling up everything, looking across your business relative to the 3%-5% longer term? Then, how much of this do you see as cyclical versus how much is company-specific, and you think you can address with the strategy that you've outlined so far in the call. Thank you for that.

Yeah. Thanks, Kevin. Let me just tackle the categories first. They obviously slowed, as I mentioned, in Q3. On a global basis, particularly for developed markets, the initial slowdown was driven by lower pricing across many of the categories, but that inflationary pressure abated. We didn't see it necessarily coming back in volumes. Clearly, underpinning all of this is just the continuous consumer uncertainty. As we talk to consumers and evaluate consumers around the world, it's not a question of them being confident. It's just the uncertainty with all the moving parts that are going on and all the noise and rhetoric. Ultimately, on a global basis, categories are now, for us, growing roughly 2% on a global basis, probably more like 3% in the first half. Obviously, it's a bit slower. That's versus the 4%-5% exit run we had in 2024.

Volumes today basically flat with pricing more or less too. If you go back, Kevin, historically, over the last 10 years, clearly, these are low levels of market growth. Whether you want to call it cyclical or not, it's clearly way below the historical averages. Our anticipation is, yeah, things will get better. I want to reiterate, if things don't get better, we are preparing our plans and our strategy to address what we need to do to grow faster in this current environment. That's not only faster top line, but faster margin growth and faster EPS to ensure that we're putting steps in place if this is to linger on for another couple of quarters. I do think it's somewhat cyclical versus historical numbers, but we're not waiting to see if it turns. We're taking steps now to ensure that we accelerate organic growth moving forward.

The next question comes from Peter Galbo with Bank of America. Please go ahead.

Hey, good morning, Noel and Stan. Thanks for taking the question.

Morning. I wanted to ask a little bit on the gross margin performance in the quarter. I know you called out maybe the acceleration in palm oil costs, and I just wanted to understand, A, how much of that is just base period effect? I mean, the raw material pressure in the margin build clearly stepped up versus the second quarter. I just want to understand, is that base period effects or is that something else? Then B, Noel, I know there's a lot of kind of geopolitical noise around it, but obviously, we have some Southeast Asia trade deals. We have political unrest in Indonesia, a lot of places where you source from. Maybe just the latest and greatest on what you're seeing kind of in the live market from a palm oil perspective. Thanks very much.

Let me start with the gross profit. First, gross profit margin was down year over year in a quarter versus Q3. I would point out Q3 of last year was the highest gross profit margin we've had since 2020. The year-on-year impact is primarily driven through greater-than-anticipated raw materials inflation. Fast and oils is the biggest driver there. The impact of lower volumes on our fixed cost leverage from our production facilities, tariffs, and the transactional FX. We also saw an impact that we talked about earlier from the formula change in Colgate Total and Latin America, as we mentioned in the prepared commentary. For our guidance, what we've laid out is that our year-to-date margin is 60.1%. We expect the full year gross margin to be roughly in line with that, which would put Q4 at 60%±.

The sequential improvement for Q4 versus Q3, we're confident in because we expect that there'll be less material inflation on a year-on-year basis. Transactional and Colgate Total impact will be partially offset by a slightly greater tariff impact. We're confident on the gross profit improvement as we go quarter to quarter, which would deliver us a gross profit margin for the year that's roughly in line with the year to date.

The next question comes from Chris Carey with Wells Fargo Securities. Please go ahead.

Hi, everybody. Thanks so much. Just to clarify that, were there anomalies in Q3 gross profit that should be easing from here over and above just the rising commodity backdrop? I just wanted to clarify that quickly. The question is around advertising spending. Colgate has increased ad spending over the years. Obviously, this is allowing for a very full and rich source of investments to support your brands. I'm also conscious that you have peers that are looking at AI and automation to drive savings in advertising. Clearly, you talked about AI quite a bit in the prepared remarks. I just wonder, with sales and categories doing what they're doing, is there any, I guess, desire or thought to think a bit more strategically about advertising spending going forward and maybe less concentrating on percentage of sales?

How can the organization be more efficient with this spending so as to get the right return profile? Thanks so much for any thoughts there. 

Yeah. Chris, let me start with the gross profit. Just again, the kind of quarter-to-quarter anomalies as we think about what will drive that. From the total impact that we talked about in Latin America, that was roughly 50 basis points or so margin, and we believe that most of that is behind us. That would be a benefit. We do see materials, gross materials easing on a year-on-year basis. That will also be a help. Now we're completely out of private label, so that is not going to impact the current period GP. Obviously, it's still in a prior year. We're confident in the GP improvement here as we go quarter to quarter.

Yeah, Chris, let me talk about the advertising question because this is one I'm spending a significant amount of time on. As we laid out our 2030 strategy, and we've talked about in previous meetings, AI and ultimately the application of AI across various vectors in our company is strategically very, very important. We've been investing not only over the last three years in that space, but we'll continue to accelerate our investment there. If I look at the year-to-date spending on advertising, roughly in line with last year's record full year number, we expect the fourth quarter to be roughly in line with the year to date. Advertising dollars and percent down slightly year-on-year as we lapped obviously the strong level of spending that we had in the year-ago quarter in 2024.

We are still spending very robustly against our brands, although we pulled back a little bit in some markets where we saw the consumer is much more challenged. We delayed some of the innovative launches that we had to later points. We adjusted spending accordingly. We're still spending against what we call return on investments. You're very much looking at leveraging our media efficiencies, as you point out, to get a much better return on the overall investment. We still expect advertising to be roughly flat this year on a percent to sale basis as we move forward. As I talked about, we will look to the savings from our SGPP to continue to fund advertising and accelerate how we're thinking about building our brands moving forward. Let me talk a little bit about AI.

This is one that certainly I've hoped that our investors have seen that we've been really out in front of this, as I talked about at CAGNY. It's a very important focus for us and a key strategic enabler for both growth and productivity as we move into the 2030 plan. We're very, very excited about that. We've spent a significant amount of money in the last two years training and upskilling our teams on horizontal AI and their ability to apply that to drive more productivity. Our independent surveys that we see would indicate that we're making strong progress versus our peer growth in terms of using AI and its implementation across the company. We've launched AI hubs using the world's leading generative AI models to ensure our people have secure access to the most advanced AI capabilities.

As I think I may have mentioned at CAGNY, this is, to me, a huge unlock to drive productivity across the organization. We'll move it into the next phase, certainly as we go into 2030, more on the vertical basis to really re-engineer our processes and drive a lot more efficiency. I thought I could talk about a couple of the areas that we're very focused on with regards to advancing AI, and particularly as we move into agentic AI, which is a next big frontier for us that we're quite excited about. Marketing and content, we will be using generative AI; it will be pivotal to transforming all of our marketing and digital strategies. We're going to significantly enhance consumer engagement through optimized, real-time, and compelling visual storytelling through AI-developed content. That's going to be exciting for us.

We have some pilots in some pretty significant markets that are showing very early, great early success. The second big focus area, as I mentioned in my upfront comments, is around innovation and how we're going to truly step up the quality and quantity of our innovation using AI and our ability to much more efficiently generate more consumer-centric concepts and get those tested and validated much quicker and incubated across core markets. That's exciting for us. As we look at some of the collaboration, as we think about agentic commerce moving forward, an area that we're really thinking about collaborating closely with some of our big retailers, whether it's Walmart and OpenAI, whether it's Amazon, all of these will afford us the opportunity to unlock the potential that agentic commerce will bring.

We're certainly thinking about strategically how to make sure our brands play at the forefront of that and that exciting change that we're going to see from shopper behavior. Rest assured, AI is right at central in terms of our strategic growth enablers for the 2030 strategy and the investments that we put in place over the last couple of years. We think position us very well to continue to maximize on the trends that we're seeing with that exciting technology.

The next question comes from Michael Lavery with Piper Sandler. Please go ahead.

Thank you. Good morning. Thanks for the question.

Ground covered already. There's been good stuff already. Just maybe a couple of quick ones on pet. Cats are gaining share of the U.S. population, you pointed out. Some innovation in the EU. Is there a similar shift there in terms of the market dynamics favoring cats? You also pointed to the 20,000 distribution point gain in the U.S. Can you give a sense of maybe some of the timing and how much of that wraps into 2026? Maybe just on inventories as well, you cited a little pressure there. Are those at the right levels now, or should we expect any more retailer reductions still to come?

Yeah, thanks, Michael, for the question. Let me more broadly cover Hill's again, and I'll address in turn some of your specific questions. Overall, given the category slowdown and impressive quarter for Hill's and what I would characterize as pretty tough circumstances, we delivered 2.5% organic ex-private label. That came with some e-commerce inventory reductions we saw at the end of the quarter from some of our retailers. Therapeutic, which I didn't talk about in my upfront comments, continues to be a real growth driver for us. The prescription diet business is doing exceptionally well with market share growth, which is obviously helping our mix and gross margin and operating margins on that business moving forward. We saw a greater impact, as we've mentioned in the upfront comment, on private label this quarter, to the tune of about 300 basis points.

Clearly, strategically, we're not in the business of producing private label. This is going to get cleaned out as we move through the fourth and into the first half of 2026, which would be terrific for the business, allowing us to really focus on the short-term growth opportunities and longer-term strategic growth opportunities that we've talked about. If I go back to the year-to-date and importantly the third quarter, we grew organic sales in almost every combination of wet, dry, treats, cat, dog, prescription diet, and science diet. It was very broad-based strength despite the slowing category. We're really pleased with the underlying structure of the business. Continued strong margin performance on the business is driven by the fundamentals, aided to be sure by a little bit lower private label. We're obviously getting more leverage through the P&L as we continue to optimize the supply chain.

We're able to do that despite obviously softer volumes in general. As the category remains sluggish and ultimately should come back medium and longer term, we'll get obviously more leverage moving through our facilities. We're gaining share across channels as well, which is terrific. The science-based innovation that we're bringing behind the increased brand investment is clearly working. Active biomes, multi-packs, a series of price pack architecture moves, getting better assortment in store, particularly on the growing segments like cat and wet, are generating real benefit for us. My compliments, obviously, to the supply chain with all the changes that we've executed over the last couple of years. Our supply chain now really seems to be executing well. Our ramp-up of Tonganoxy is obviously unlocking a lot of opportunities for growth in the wet segment and driving more efficiency. Overall, a pretty strong performance despite the slowdown in the market.

I think longer term, as we've always said, the dynamics of this category will continue to be excellent. Even though we're seeing some slowdown, the strategic growth segments are growing fast, and we have an opportunity to get our fair share in those segments. Lastly, I would say the Prime acquisition that we made in Australia continues to perform really, really well ahead of expectations. We're learning a lot about fresh in that market, and we will continue, obviously, to fuel that growth in Australia and learn from that important segment.

The next question comes from Andrea Teixeira with JPMorgan. Please go ahead.

Thank you. Good morning. Are you planning any selective pricing to offset the additional commodities headwinds? A second part of that is that with FX coming in better than anticipated, isn't it positive for especially latent transactional FX into 2026 and even in the fourth quarter as you phase out the total impact?

Yeah. Andrea, why don't I take the first one? On the pricing, as you go through, Noel's covered pricing here on what we would look at. The pricing actions we have in place try to address in balance with competition as well as the commodities that we see. FX clearly did come in favor here over the past quarter. If it stays in a current place, it should be a tailwind for us heading forward. At the current spot rate, we still see it as a flat single-digit negative impact for the year, but Q4 would be more favorable than Q3. Europe has the biggest marginal benefit, but most currencies in general have moved favorable. In fact, you mentioned Latin America currencies. Those have also moved recently, which is a benefit to the business. FX becomes a bit of a tailwind here at the current spot rate.

Yeah. The other thing, Andrea, I'd mention is that we were positive pricing in every single division in the third quarter, which again, I think is a clear indication that our brands are strong. The investment we put behind them over the years is allowing us to offset some of the commodity inflation and some of the foreign exchange inflation that we've had in the first half. Overall, we're encouraged with that, and we will continue to look for pricing opportunities as we move forward, certainly as we look to balance the volume component of the business in the medium and longer term.

The next question comes from Olivia Tong with Raymond James. Please go ahead.

Great. Thanks. Can you talk a little bit about offsets to keep EPS unchanged? Gross margin guide obviously came in 50 basis points, but you're maintaining the lowest and lowest EPS. Are you expecting to be on the lower end of the range, or is there some kind of offset that we should be mindful of? As we think about this more challenged environment, is there more that should be done with respect to restructuring, given the current backdrop? Thanks.

Let's talk a little bit about the guidance on EPS. If you kind of go back and look at the overall guidance, we said that we still expect net sales to be up low single digits, and that's including a flat to low single-digit negative impact from foreign exchange, though that improves as we get to the back half of the year. We updated our organic sales growth to be roughly in line with the year-to-date, which would indicate it'd be around 1.2% for the year. That includes a 70 basis point impact from the exit of private label. As you're thinking about run rate going out, it's important to keep that in mind. On gross profit margin, we said we roughly align with the year-to-date gross profit margin of 60.1%, including advertising roughly in line with the full year of last year. We've held our EPS guidance.

If you step back in our commentary the last few years, we've made significant changes to the business model. The strength of that business model enables us to weather the challenges that we had here in Q3 and still deliver bottom-line dollar-based EPS growth. We expect to be able to continue that here for this year. On the restructuring question, for our Sales Growth and Productivity Program, this is designed for two facets. First, we're doing this, we believe, from a position of strength to enable us to fund incremental investments, as well as the second piece of delivering savings to continue to deliver dollar-based earnings growth. It facilitates the changes that help us make us more flexible, simplify our processes, increase our speed and efficiency.

The program's consistent with what we announced last quarter, with estimated charges of $200 million to $300 million and concluding by the end of 2028. We anticipate those kind of first charges to start to roll through in the fourth quarter. We're doing a lot of planning. We're going to execute this carefully because we're changing the way we work, not just slashing cost. It's important that we're looking to design and allow the future fit for our organization, which aligns with our 2030 strategy. That's going to include investments in things like omnichannel demand generation, increased innovation, scaling our capabilities. Noel just covered AI and agentic AI, deep investments in those areas, and educating our teams at the same time to be able to go execute that. This also will help us continue to drive flexibility and personalization in the supply chain.

We talked about those investments that we made, and we think that will continue to benefit us going forward.

Excuse me, Olivia, if I can just add one thing to what Stan said. We spent a lot of time over the last 12 months talking about building flexibility into the P&L. I think that is the key thing from that standpoint, which is we worked all through 2024 to build that. We used some of that. We're still building flexibility in the P&L. Again, when we think about achieving our targets, we're still continuing to think about that. I think if you look at the 2025 results, we've had incremental tariffs. Year over year, we have foreign exchange. We've had higher raw materials, the category slowdown, what have you. It's that focus on the flexibility that allows us to get to that.

We're going to use that up as we go through the year to deal with headwinds, but that's really the focus of building that up in the first place.

The next question comes from Steve Powers with Deutsche Bank. Please go ahead.

Great. Good morning. I guess picking up on some of that. Noel, when you step back and you think about the initiatives that you opened with and that Stan just walked through in support of SGPP, your innovation model, omnichannel diversification, RGM, etc., all underpinned by AI and predictive analytics, those all seem like the right points of emphasis. I guess a couple of questions around that. How do you think about the upfront costs of all those things in the aggregate? Number one. Number two, to what extent are they really points of category acceleration or points of Colgate-specific differentiation versus more just the cost of doing business these days? If I was going to be devil's advocate, I'd say that those thematically, that's what a lot of companies are doing. I guess all of that in terms of how that plays into your 2026 planning, if you could.

Yeah. Thanks, Steve. I think we clearly want to look at these as a way to gain a competitive advantage in the market, but more importantly, utilize the capabilities to drive incremental category growth for our retailers and for us. Let me start with innovation. We're learning a lot about how to use technology to innovate faster and to get better premium innovation in the market that's validated expeditiously in terms of how we've looked at it before. All of that is intended on giving us a way to go to our retailers, partner with our retailers with better innovation, faster, and in more quantity than we've done before. It's going to allow us to hopefully accelerate that if we gain a competitive advantage on that.

Getting a clear understanding of how to use, let's take agentic AI and how to make sure that we're participating in them, once again, drives premiumization, drives more purchase intent. The three mores, more money, more households, more volume, allows us to really get much more personalized with our messaging, which will drive incremental consumption in the category. All of that, if we believe we're doing it right and partnering with our retailers in an effective way, should drive more category growth. Now, taking AI aside from the top-line aspect of the company and the growth aspect, it's using it to really effectively be more productive internally within the organization. Let me take demand planning as an example.

Colgate-Palmolive (CL) Q3 2025 Earnings Call Transcript

Company Participants